Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
 2018 Annual Meeting - EconoTimes)
RANCHO CORDOVA, Calif., March 28, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) today announced that two late-breaking abstracts involving the use of Cesca’s X-Series™ technologies for cell processing have been accepted for presentation as posters at the ISCT 2018 Annual Meeting, which is being held May 2-5, 2018 at the Palais des Congrès de Montréal in Montreal, Québec. Details of the poster presentations are as follows:
Abstract 2963114: Novel buoyancy based cell selection: X-BACS™ Technology
Poster number/abstract ID number: 380
Poster Session 2: May 4, 2018, 5:00-6:30PM
Abstract 2963911: Quick and easy method for removal of DMSO from thawed cellular products
Poster number/abstract ID number: 381
Poster Session 2: May 4, 2018, 5:00-6:30PM
About the International Society for Cellular Therapy (ISCT) Annual Meeting
ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients' lives. ISCT members gain access to an influential global community of peers, experts, and organizations invested in cell therapy. ISCT offers a unique collaboration between academia, regulatory bodies, and industry partners in cell therapy translation.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
